SCAs - Ataxia UK

SCAs

Reflections on the Ataxia UK Annual Conference 2023

On Friday 20th and Saturday 21st October 2023, Ataxia UK held their first ever hybrid in-person and virtual annual conference for families affected by ataxia. The conference, which took place

Reflections on the Ataxia UK Annual Conference 2023 Read More »

US FDA and European Commission grants VICO Therapeutics Orphan Drug Designation for VO659, an Investigational Therapy for Spinocerebellar Ataxia 

Spinocerebellar ataxias (SCAs) are a group of rare, progressive hereditary genetic disorders that affects the cerebellum, brain stem and spinal cord. Currently, more than 30 types of SCAs have been identified. SCAs are caused by genetic mutations,

US FDA and European Commission grants VICO Therapeutics Orphan Drug Designation for VO659, an Investigational Therapy for Spinocerebellar Ataxia  Read More »

Donate Now
Scroll to Top